The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Results of treatment changes in patients with apparently drug‐resistant chronic epilepsy
Abstract
Objective: It has long been known that the response to treatment in newly diagnosed epilepsy is better than in chronic epilepsy. However, in the past 15 years, 8 major new antiepileptic drugs have been licensed, and the effect of this wider range of treatment options on prognosis has not been fully assessed. The aim of this study was to quantify the effect of adding a previously unused antiepileptic drug to the treatment regimen in adults with uncontrolled chronic epilepsy that had been resistant to previous antiepileptic drug treatment. Methods: A total of 265 drug additions were studied in 155 adult patients with chronic epilepsy (defined as epilepsy active at least 5 years after and initiation of therapy). Results: About 16% of all drug introductions resulted in seizure freedom (defined as seizure freedom at last follow‐up for 12 months or longer), and a 50 to 99% seizure reduction occurred in a further 21%. Of the 155 patients, 28% were rendered seizure free by a drug introduction. Clinical factors associated with a better effect were fewer previously used antiepileptic drugs, shorter duration epilepsy, and idiopathic epilepsy. Interpretation: This study provides a quantitative estimate of the value of changing drug therapy in patients in whom seizures were previously uncontrolled by previous therapy. The application of a systematic protocol to the treatment of chronic epilepsy will improve seizure control in a substantial proportion of cases. The rather nihilistic view that intractability is inevitable if seizure control is not obtained within a few years of the onset of therapy is incorrect. Ann Neurol 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Long-Term Prognosis of Seizures with Onset in Childhood
Sillanpää, M., Jalava, M., Kaleva, O., & Shinnar, S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806113382402 · Cited by 726
French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000123693.82339.fc · Cited by 654
Remission of Seizures and Relapse in Patients with Epilepsy
Annegers, J. F., Hauser, W. A., & Elveback, L. R. (1979) · Epilepsia · doi:10.1111/j.1528-1157.1979.tb04857.x · Cited by 622
Drug Resistance in Epilepsy: Putative Neurobiologic and Clinical Mechanisms
Schmidt, D., & Löscher, W. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.54904.x · Cited by 482
Shorvon, S. D., Löwenthal, A., Janz, D., Bielen, E., Loiseau, P., & for the European Levetiracetam Study Group (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb00323.x · Cited by 451
Self-citationFrench, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000123695.22623.32 · Cited by 407
Remission of epilepsy: results from the National General Practice Study of Epilepsy
Cockerell, O. C., Sander, J. W. A. S., Hart, Y. M., Shorvon, S. D., & Johnson, A. L. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91208-8 · Cited by 384
Self-citationDiagnosing refractory epilepsy: response to sequential treatment schedules
Mohanraj, R., & Brodie, M. J. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01215.x · Cited by 340
Cockerell, O. C., Johnson, A. L., Sander, J. W. A. S., & Shorvon, S. D. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01075.x · Cited by 311
Self-citation
Cited by
Kwan, P., Arzimanoglou, A., Berg, A. T., Brodie, M. J., Allen Hauser, W., Mathern, G., Moshé, S. L., Perucca, E., Wiebe, S., & French, J. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02397.x · Cited by 4,877
Patterns of treatment response in newly diagnosed epilepsy
Brodie, M. J., Barry, S. J. E., Bamagous, G. A., Norrie, J. D., & Kwan, P. (2012) · Neurology · doi:10.1212/wnl.0b013e3182563b19 · Cited by 931
The consequences of refractory epilepsy and its treatment
Laxer, K. D., Trinka, E., Hirsch, L. J., Cendes, F., Langfitt, J., Delanty, N., Resnick, T., & Benbadis, S. R. (2014) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2014.05.031 · Cited by 679
Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemma
Löscher, W., & Schmidt, D. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03024.x · Cited by 590
Key factors in the discovery and development of new antiepileptic drugs
Bialer, M., & White, H. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2997 · Cited by 542
Intractable epilepsy: management and therapeutic alternatives
Schuele, S. U., & Lüders, H. O. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70108-x · Cited by 344
The pharmacological treatment of epilepsy in adults
Perucca, E., & Tomson, T. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70047-3 · Cited by 334
Quantifying the response to antiepileptic drugs: Effect of past treatment history
Schiller, Y., & Najjar, Y. (2008) · Neurology · doi:10.1212/01.wnl.0000286959.22040.6e · Cited by 313
Manford, M. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8394-2 · Cited by 299
Antiepileptic drug therapy the story so far
Brodie, M. J. (2010) · Seizure · doi:10.1016/j.seizure.2010.10.027 · Cited by 298
Tatum, W. O. (2012) · Journal of Clinical Neurophysiology · doi:10.1097/wnp.0b013e31826b3ab7 · Cited by 273
The natural history and prognosis of epilepsy
Beghi, E., Giussani, G., & Sander, J. W. (2015) · Epileptic Disorders · doi:10.1684/epd.2015.0751 · Cited by 268
Management of Drug-Resistant Epilepsy
Nair, D. R. (2016) · Continuum · doi:10.1212/con.0000000000000297 · Cited by 68
“Approximately 15% to 20% of patients who have failedmore than two anticonvulsantsmay become seizure free after subsequent trials, although conditions that are amenable to epilepsy surgery, such as mesial temporal sclerosis, are less likely to respond to further medication trials.(4,11) Approximately 30% of patients wi…”
Background
Metadata
- Authors
- Luciano, A. L., & Shorvon, S. D.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2007-10
- Volume
- 62
- Issue
- 4
- Pages
- 375-381
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2105359051
- Cited by
- 325
- References
- 22
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.